MET and cancer: It is able to target E2F Transcription Factor 3 (E2F3), DNA methyltransferase 1 (DNMT1), met proto-oncogene (MET) and Rapamycin-insensitive companion of mTOR (Rictor) and in EC cells it seems to be down-regulated through CpG hypermethylation, promoting cancer development and progression [77].